Vaccine-Associated Measles in a Hematopoietic Cell Transplant Recipient: Case Report and Comprehensive Review of the Literature

Sandy Y. Chang,1 Anjali Bish,2 Karolina Faysman,3 Gary J. Schiller,3 Daniel Z. Usan,1 and Ashrit Multani14

1Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA, 2Clinical Epidemiology and Infection Prevention, UCLA Health, Los Angeles, California, USA, and 3Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA

Measles is a worldwide viral disease that can cause fatal complications in immunocompromised hosts such as hematopoietic cell transplant (HCT) recipients. The live attenuated measles, mumps, and rubella (MMR) vaccine is generally contraindicated post-HCT due to the risk for vaccine-associated measles. This, combined with decreasing vaccination rates due to vaccine hesitancy and the coronavirus disease 2019 pandemic, raises significant concerns for a measles resurgence that could portend devastating consequences for immunocompromised hosts. Multiple guidelines have included criteria to determine which HCT recipients can safely receive the MMR vaccine. Here, we report a case of vaccine-associated measles in a HCT recipient who met guideline-recommended criteria for MMR vaccination. The objective of this article is to query these criteria, highlight the importance of MMR vaccination, and comprehensively review the literature.

Keywords. hematopoietic cell transplant; immunocompromised; measles; MMR vaccine; vaccine.

CASE REPORT

A 22-year-old man with pre-B-cell acute lymphoblastic leukemia underwent myeloablative allogeneic hematopoietic cell transplantation (HCT) from a HLA-identical unrelated donor using a peripheral blood allograft 4 years prior to presentation. His post-HCT course was complicated by acute graft-vs-host disease (GVHD) of the skin, eyes, gastrointestinal tract, and liver requiring intensified immunosuppression with tacrolimus, itacitinib, and prednisone. After clinical resolution of GVHD, all iatrogenic immunosuppression was discontinued on day +1335.

Due to the patient’s concerns regarding recent measles outbreaks and because he met 2009 American Society for Blood and Marrow Transplantation (ASBMT), 2013 Infectious Diseases Society of America (IDSA), and 2017 National Comprehensive Cancer Network (NCCN) guideline criteria for immunization, he received the measles, mumps, and rubella (MMR) vaccine on day +1408 (73 days after discontinuing immunosuppressive medications). Nine days postvaccination, he presented to the Hematology and Oncology Clinic with fevers up to 40°C (104°F), sore throat, nonproductive cough, and tender cervical lymphadenopathy. Twelve days postvaccination, he returned to the Hematology and Oncology Clinic after an asymptomatic, faint pink, maculopapular rash developed on his face and spread to his torso and upper extremities (Figure 1). He did not have conjunctivitis or coryza. He denied any recent measles exposures, sick contacts, or international travel.

After consultation with Transplant Infectious Diseases, Clinical Epidemiology and Infection Prevention, and the Los Angeles County Department of Public Health, a diagnostic evaluation for vaccine-derived measles was performed. Serum measles immunoglobulin M antibody was positive and immunoglobulin G antibody was negative (Los Angeles County Public Health Laboratory, Los Angeles, California). Measles RNA was detected by polymerase chain reaction in urine and throat specimens (Los Angeles County Public Health Laboratory). Viral genotyping by sequence analysis confirmed the strain to be genotype A (vaccine-derived) measles (California Department of Public Health Viral and Rickettsial Disease Laboratory, Richmond, California). He received a single dose of intravenous immunoglobulin (IVIG) 400 mg/kg. His symptoms resolved without sequelae. Despite his attendance at the Hematology and Oncology Clinic where other vulnerable individuals with solid tumor malignancies, hematologic malignancies, and HCT recipients were also present, no secondary cases occurred.

DISCUSSION

The measles vaccine was first licensed for use in the United States in 1963. Subsequently, measles incidence declined rapidly and it was declared eliminated in the United States in 2000 [1, 2]. However, measles incidence and deaths have been increasing globally, particularly in low- and middle-income countries where vaccination rates have regressed since 2010 and are far from the Global Vaccine Action Plan targets [2–11]. Vaccination rates have declined further during the coronavirus
disease 2019 pandemic, heightening serious concerns for a measles resurgence [2, 9, 10, 12, 13].

Belonging to the *Paramyxoviridae* family, measles virus is a single-stranded, negative-sense, enveloped RNA virus that exists worldwide. As an airborne infection, measles is the most contagious transmissible viral disease known, with a single case resulting in an average of 12–18 secondary cases in susceptible persons [1]. Measles can occur in fully vaccinated persons either due to absence of immunization (primary vaccine failure) or due to waning immunity (secondary vaccine failure) [5, 14, 15].

Wild-type measles classically manifests with a prodrome lasting 2–4 days consisting of fever and at least 1 of the "3 C's" (cough, coryza, and conjunctivitis) [1]. Usually between 2 and 4 days after fever onset, the typical erythematous maculopapular rash appears first on the face and head, and then spreads to the trunk and extremities [1]. The rash then fades in the order in which it appeared, usually resolving within 7 days after onset in uncomplicated cases [1]. Koplik spots (small bluish-white plaques on the buccal mucosa) are considered pathognomonic and appear in up to 70% of cases [1]. In relation to rash onset, they present 1–2 days before and may persist for 1–2 days after [1]. Measles generally resolves without sequelae. However, rare but devastating consequences such as measles inclusion body encephalitis (MIBE), subacute sclerosing panencephalitis, Hecht’s giant cell pneumonia (GCP), and death can occur in specific vulnerable populations, including immunocompromised hosts such as HCT recipients [1]. Measles has been shown to compromise acquired immunity to prior infections and vaccinations, highlighting the additional benefits of measles vaccination in its ability to preserve existing protection against other pathogens [16, 17]. Measles outbreaks also place a significant financial burden on a health care system that is already under duress, with a median total cost per outbreak of $152,308 (range, $9862–$1,063,936) [18]. Of note, the 2019 measles outbreak in Washington was estimated to have an overall societal cost of $3.4 million [19].

To identify published cases of vaccine-associated measles, a systematic electronic search of PubMed and Google Scholar using the keywords “measles vaccine,” “measles, mumps, and rubella vaccine,” “MMR vaccine,” and “vaccine-associated measles” without date or language restrictions was conducted. Vaccine-associated measles is a rare occurrence, with 66 laboratory-confirmed cases in measles vaccine recipients (including our patient) published to date (Table 1) [20–38]. Cases were confirmed by genotyping or by the combination of another diagnostic methodology (eg, culture, antigen, or serology) in conjunction with clinical criteria (eg, measles-like illness occurring soon after measles vaccination, absence of known exposures, and/or lack of secondary cases), thereby rendering the diagnosis of vaccine-associated measles far more likely than wild-type measles. Of these, 3 had severe complications including MIBE, GCP, and/or death, and all had an underlying immunocompromising condition [20, 21, 23–25]. The remaining 63 (95.5%) cases were self-limiting and resolved without sequelae. The only other published case of vaccine-associated measles in a HCT recipient was a 5-year-old boy whose clinical manifestations resolved without complications [30]. Additional cases have also been suspected clinically to be vaccine-associated but were not microbiologically-confirmed [39–42]. Choe et al reported that patients with vaccine-associated measles may be less likely to develop the "3 C’s" than patients with wild-type measles, and therefore suggested that these findings may help differentiate wild-type measles from vaccine-associated measles [32]. However, our case report and literature review do not support this hypothesis. Ultimately, laboratory confirmation is required to distinguish between the 2, which is critical to inform infection prevention and control practices including contact tracing [22, 29, 30, 35, 43]. Importantly, including our patient, no laboratory-confirmed secondary cases of vaccine-associated measles have been reported [30, 44]. One brief case report of possible brother-to-sister transmission of measles after MMR vaccination was described, but this was a clinical diagnosis that was not microbiologically-confirmed [42].

According to the 2009 ASBMT, 2013 IDSA, and 2017 NCCN guidelines, the live attenuated MMR vaccine can be administered to seronegative HCT recipients who are >2 years post-HCT, with neither chronic GVHD nor ongoing immunosuppression, and if at least 8–11 months (or earlier if there is a measles outbreak) have elapsed since the last dose of IVIG [45–47]. These recommendations are based on studies showing the efficacy and safety of MMR vaccination.
vaccination in HCT recipients [48]. Our patient met the criteria established in the ASBMT, IDSA, and NCCN guidelines but acquired measles via vaccination nonetheless. While he fortunately did not suffer any severe adverse consequences, questions were raised regarding the safety of the MMR vaccine in HCT recipients who meet these guideline-recommended criteria. Carpenter and Englund offered a slightly different approach by suggesting it would be considered safe to give the MMR vaccine when HCT recipients are at least 2 years out from HCT, at least 1 year off systemic immunosuppressive therapy, and at least 8 months out from any prior IVIG dose (also known as the “2-1-8” Rule) [49]. Since our patient had received the MMR vaccine only 73 days after discontinuation of iatrogenic immunosuppression, he would have been ineligible to receive the MMR vaccine according to the “2-1-8” Rule.

The resurgence of measles has led to a closer examination of the relative benefits and risks of MMR vaccination in immunocompromised hosts such as HCT recipients. However, data on this are scarce. A systematic review by Croce et al evaluating the safety and efficacy of live vaccines in immunocompromised hosts included 152 HCT recipients who received the MMR vaccine within 2 years post-HCT [50]. Twenty-seven of these patients were receiving immunosuppressive therapy at the time

Table 1. Summary of Published Cases of Laboratory-Confirmed Vaccine-Associated Measles in Measles Vaccine Recipients

| First Author, Year [Reference] | No. of Case | Age | Underlying Condition(s) | Time From MMR Vaccine to Symptom Onset | Clinical Manifestations (No. [%]) | Outcome |
|-------------------------------|------------|-----|-------------------------|--------------------------------------|----------------------------------|---------|
| Mawhinney, 1971 [20]          | 1          | 10 months | Dysgammaglobulinemia   | 7 days                               | Fever, rash, GCP                 | Death   |
| Monafo, 1994 [21]             | 1          | 17 months | SCID                   | 2 months                             | Fever, rash, hepatitis, GCP      | Death   |
| Kobune, 1995 [22]             | 1          | 1 year   | NS                     | 7 days                               | Fever                            | Recovery |
| Angel, 1998 [24]              | 1          | 20 years | HIV/AIDS (CD4+ T-lymphocyte count undetectable) | 330 days | Fever, night sweats, chills, cough, weight loss, GCP | Recovery |
| Bitnun, 1999 [25]             | 1          | 21 months | CD8+ T-lymphocyte deficiency, dysgammaglobulinemia | 8.5 months | Fever, irritability, vomiting, MIBE | Death   |
| Jenkin, 1999 [26]             | 1          | 17 months | NS                     | 15 days                              | Fever, rash                       | Recovery |
| Goon, 2001 [27]               | 1          | 14 months | HIV (CD4+ T-lymphocyte count 570 cells/µL) | 10 days | Fever, anorexia, diarrhea, rash | Recovery |
| Berggren, 2005 [28]           | 1          | 13 months | None                   | 10 days                              | Fever, cough, coryza, conjunctivitis, rash, anorexia, cervical LAD, Koplik spots | Recovery |
| Nestibo, 2012 [29]            | 1          | 15 months | None                   | 12 days                              | Fever, irritability, cough, conjunctivitis, rash, cervical LAD | Recovery |
| Hau, 2013 [30]                | 1          | 5 years   | HCT                    | 6 days                               | Fever, cough, coryza, conjunctivitis, rash | Recovery |
| Murti, 2013 [31]              | 1          | 2 years   | None                   | 37 days                              | Fever, cough, coryza, conjunctivitis, rash | Recovery |
| Choe, 2014 [32]               | 40         | 12–23 months | NS                    | 7–14 days                            | Fever (34 [85%]), rash (38 [95%]), cough (14 [35%]), coryza (17 [43%]), conjunctivitis (4 [10%]) | Recovery |
| Kurata, 2014 [33]             | 1          | 23 years   | None                   | 18 days                              | Fever, rash, coryza, conjunctivitis, Koplik spots | Recovery |
| Sood, 2017 [34]               | 1          | 13 months | None                   | 9 days                               | Fever, cough, coryza, rash       | Recovery |
| Xu, 2017 [35]                 | 8          | 8 months–26 years | NS                    | 4–11 days                            | Fever (8 [100%]), rash (8 [100%]), cough (3 [38%]), conjunctivitis (3 [38%]), coryza (2 [25%]), Koplik spots (2 [25%]), LAD (1 [13%]) | Recovery |
| Churchill, 2018 [36]          | 1          | 40 years   | Postpartum             | 10 days                              | Fever, cough, rash, malaise, myalgia | Recovery |
| Miauton, 2020 [37]            | 1          | 35 years   | RRMS (on natalizumab)  | 7 days                               | Fever, rash, myalgia, fatigue    | Recovery |
| Yu, 2020 [38]                 | 2          | 11–53 months | NS                    | 8–10 days                            | Fever (2 [100%]), rash (2 [100%]) | Recovery |
| Chang (2021, present case)    | 1          | 22 years   | ALL, HCT               | 9 days                               | Fever, sore throat, cough, cervical LAD, rash | Recovery |

Abbreviations: ALL, acute lymphoblastic leukemia; GCP, giant cell pneumonitis; HCT, hematopoietic cell transplantation; HIV, human immunodeficiency virus; LAD, lymphadenopathy; MIBE, measles inclusion body encephalitis; MMR, measles, mumps, and rubella; NS, not specified; RRMS, relapsing-remitting multiple sclerosis; SCID, severe combined immunodeficiency.
of vaccination [50]. A limitation of this review is that many of the included studies did not document whether adverse events were observed. One child who had undergone high-dose chemotherapy and autologous stem cell rescue had relapse of her underlying disease after MMR vaccination, but the relative time points of each event were unknown [50]. Multiple studies showed clinical protection from measles and immunogenicity to measles ranging from 33% to 78%, but these studies were heterogeneous in regard to patient population, timepoint post-HCT, iatrogenic immunosuppression at the time of vaccination, and immunogenicity assessment [50]. Because of these and other limitations, the authors concluded that the identified data were not sufficiently robust to change the currently available international vaccination recommendations on live vaccines under immunosuppression or within 2 years post-HCT [50].

Knowledge of the online ecology of vaccine views can help combat the dangers of homemade remedies, falsehoods, dismissal of expert advice, and antivaccination beliefs before they become dominant in a decade as predicted [51, 52]. Because vaccine hesitancy is largely related to distrust of the medical community and concerns regarding vaccine safety, greater communication is urgently needed to build trust based on scientific evidence and transparency. There should be increased awareness about publicly available resources such as the Centers for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiological Research (WONDER) interface that can provide up-to-date information regarding vaccine safety by evaluating reports submitted to the Vaccine Adverse Event Reporting System [52, 53]. While adverse events have been associated with the MMR vaccine, it has an acceptable safety profile and the risks of a natural measles infection far outweigh the risks associated with MMR vaccination for eligible persons [1].

Measles can lead to serious complications in immunocompromised hosts such as HCT recipients, and the MMR vaccine may not be safe and effective for the vast majority of this population. To protect these vulnerable individuals, there is a pressing need to optimize vaccination rates in eligible persons, particularly their close contacts [54]. Compared to current ASBMT, IDSA, and NCCN guideline-recommended criteria, the “2–1–8” Rule deserves further study as a strategy for MMR vaccination of HCT recipients [49].

Notes

Acknowledgments. We extend our deepest gratitude to the Los Angeles County Department of Public Health and California Department of Public Health for their assistance and expertise in diagnosing and caring for our patient.

Author contributions. S. Y. C. and A. M. conceived and designed the work and drafted the manuscript. All authors critically reviewed and revised the manuscript and approved the final version of the manuscript to be published.

Patient consent statement. The patient’s written consent was obtained. The University of California, Los Angeles Institutional Review Board approval was not required due to this study not constituting human subjects research.

Potential conflicts of interest. All authors: No reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Strebil PM, Orenstein WA. Measles. N Engl J Med 2019; 381:349–57.
2. Patel MK, Goodson JL, Alexander JP Jr, et al. Progress toward regional measles elimination—worldwide, 2000–2019. MMWR Morb Mortal Wkly Rep 2020; 69:1708–5.
3. Chard AN, Gacic-Dobo M, Dillois MS, et al. Routine vaccination coverage—worldwide. 2019. MMWR Morb Mortal Wkly Rep 2020; 69:1706–10.
4. Patel MK, Antoni S, Nededek Y, et al. The changing global epidemiology of measles, 2013–2018. J Infect Dis 2020; 222:1117–28.
5. Zucker JR, Rosen JB, Swamini M, et al. Consequences of undervaccination—measles outbreak, New York City, 2018–2019. N Engl J Med 2020; 382:1609–17.
6. Yang W. Transmission dynamics of and insights from the 2018–2019 measles outbreak in New York City: a modeling study. Sci Adv 2020; 6:eaa44037.
7. Lu L, Roland E, Shearer E, et al. Notes from the field: measles outbreak associated with International Air Travel—California, March–April 2017. MMWR Morb Mortal Wkly Rep 2020; 69:803–4.
8. Klas P. The tragedy of measles. N Engl J Med 2020; 383:905–7.
9. Local Burden of Disease Vaccine Coverage Collaborators. Mapping routine measles vaccination in low- and middle-income countries. Nature 2020; 589:415–9.
10. Cutts FT, Ferrari MJ, Krause LK, et al. Vaccination strategies for measles control and elimination: time to strengthen local initiatives. BMC Med 2021; 19:2.
11. Li X, Mukandavire C, Cucunubá ZM, et al; Vaccine Impact Modelling Consortium. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet Glob Health 2021; 9:e1383–908.
12. Bode S, Gowda C, Mangini M, Kemper AR. COVID-19 and primary measles vaccination rates in a large primary care network [manuscript published online ahead of print 19 November 2020]. Pediatrics 2020. doi:10.1542/peds.2020-035576.
13. Bramer CA, Kimmins LM, Swanson R, et al. Decline in child vaccination coverage during the COVID-19 pandemic—Michigan care improvement registry, May 2016–May 2020. MMWR Morb Mortal Wkly Rep 2020; 69:630–1.
14. Gibney KB, Attwood LO, Nicholson S, et al. Emergence of attenuated measles illness among IgG-positive/IgM-negative measles cases: Victoria, Australia, 2008-2017. Clin Infect Dis 2020; 70:1060–7.
15. Hubiche T, Brazier C, Vabret A, et al. Measles transmission in a fully vaccinated closed cohort: data from a nosocomial clustered cases in a teenage psychiatric unit. Pediatr Infect Dis J 2019; 38:e230–2.
16. Mina MJ, Rula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 2019; 366:599–606.
17. Petrova VN, Sawatsky B, Han AX, et al. Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Sci Immunol 2019; 4:eaay6125.
18. Pike J, Leidner AJ, Gastaladiay PA. A review of measles outbreak cost estimates from the United States in the postelimination era (2004–2017): estimates by perspective and cost type. Clin Infect Dis 2020; 71:1568–76.
19. Petersen JA, Skidmore KD, Wang Y, et al. Characterizing measles vaccination in the United States in the postelimination era (2004–2017): estimates by perspective and cost type. Clin Infect Dis 2020; 71:1568–76.
20. Mawhinney H, Allen IV, Beare JM, et al. Dysgammaglobulinaemia complicated after measles vaccination. Vaccine 1994; 12:380–1.
21. Menafo WJ, Haslam DB, Roberts RL, et al. Disseminated measles infection after vaccination. Vaccine 1995; 13:370–2.
22. Centers for Disease Control and Prevention. Measles immunosurveillance following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996; 45:603–6.
23. Angel JB, Walpita P, Lanch RA, et al. Vaccine-associated measles pneumonia in an adult with AIDS. Ann Intern Med 1998; 129:104–6.
24. Bitun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855–61.
25. Jenkins GA, Chabo D, Kelly HA, et al. What is the cause of a rash after measles-mumps-rubella vaccination? Med J Aust 1999; 171:194–5.
26. Goon P, Cohen B, Jin L, et al. MMR vaccine in HIV-infected children—potential hazards? Vaccine 2001; 19:3816–9.
27. Berggren KL, Tharp M, Boyer KM. Vaccine-associated “wild-type” measles. Pediatr Dermatol 2005; 22:130–2.
29. Nestibo I, Lee BE, Fonseca K, et al. Differentiating the wild from the attenuated during a measles outbreak. Paediatr Child Health 2012; 17:e32–3.
30. Hau M, Schwartz KL, Frenette C, et al. Local public health response to vaccine-associated measles: case report. BMC Public Health 2013; 13:269.
31. Murti M, Krajden M, Petric M, et al. Case of vaccine-associated measles five weeks post-immunisation, British Columbia, Canada, October 2013. Euro Surveill 2013; 18:2049.
32. Choi JY, Eom HS, Bae GR. Vaccine-associated measles in the low-incidence country of Korea over a 10-year period. Ipn J Infect Dis 2014; 67:180–3.
33. Kurata T, Kanbayashi D, Kinoshita H, et al. Late onset of vaccine-associated measles in the low-incidence country of Korea over a 10-year period. Jpn J Infect Dis 2014; 127:e3–4.
34. Sood SB, Suthar K, Martin K, Mather K. Vaccine-associated measles in an immunocompetent child. Clin Case Rep 2017; 5:1765–7.
35. Xu CP, Li MH, He HQ, et al. Laboratory diagnosis of vaccine-associated measles in Zhejiang Province, China. J Microbiol Immunol Infect 2017; 50:578–85.
36. Churchill L, Rizzuti FA, Fonseca K, Kim J. Vaccine-associated measles in a healthy 40-year-old woman. CMAJ 2018; 190:E1046–8.
37. Miauton A, Tan R, Pantazou V, et al. Vaccine-associated measles in a patient treated with natalizumab: a case report. BMC Infect Dis 2020; 20:753.
38. Yu EJ, Kim WD, Kim YJ. Two cases of vaccine-associated measles in Daegu, South Korea, 2019. Pediatr Infect Vaccine 2020; 5:205.
39. Mitus A, Holloway A, Evans AE, Enders JF. Attenuated measles vaccine in children with acute leukemia. Am J Dis Child 1962; 103:413–8.
40. Mihatcsh MJ, Ohnacker H, Just M, Nars PW. Lethal measles giant cell pneumonia after live measles vaccination in a case of thymic alymphoplasia Gitlin. Helv Paediatr Acta 1972; 27:143–6.
41. Valmari P, Lanning M, Tuokko H, Kouvalainen K. Measles virus in the cerebrospinal fluid in postvaccination immunosuppressive measles encephalopathy, Pediatr Infect Dis J 1987; 6:59–63.
42. Millson DS. Brother-to-sister transmission of measles after measles, mumps, and rubella immunisation. Lancet 1989; 1:271.
43. Roy F, Mendoza L, Hiebert J, et al. Rapid identification of measles virus vaccine genotype by real-time PCR. J Clin Microbiol 2017; 55:735–43.
44. Greenwood KF, Hatz R, Ware RS, Lambert SB. A systematic review of human-to-human transmission of measles vaccine virus. Vaccine 2016; 34:2531–6.
45. Tommyln M, Chiller T, Einsole H, et al; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and MarrowTransplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143–238.
46. Rubin LG, Levin MJ, Liangman P, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44–100.
47. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14:882–913.
48. Ljungman P, Fridell E, Lönnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159:610–5.
49. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood 2016; 127:2824–32.
50. Croce E, Hatz C, Jonker EF, et al. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation—a systematic review of randomized trials, observational studies and case reports. Vaccine 2017; 35:1216–26.
51. Johnson NF, Velásquez N, Restrepo NJ, et al. The online competition between pro- and anti-vaccination views. Nature 2020; 582:230–3.
52. Nahum A, Drekonja DM, Alpern JD. The erosion of public trust and SARS-CoV-2 vaccines—more action is needed. Open Forum Infect Dis 2021; 8:ofaa657.
53. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, et al. MMR vaccine adverse drug reactions reports in the CDC WONDER system, 1989-2019. Open Forum Infect Dis 2020; 7:ofaa211.
54. Majeed A, Harris Z, Brucks E, et al. Revisiting role of vaccinations in donors, transplant recipients, immunocompromised hosts, travelers, and household contacts of stem cell transplant recipients. Biol Blood Marrow Transplant 2020; 26:e38–50.